```html

Xanthoma Eruptum – A Complete Patient Guide

Overview

Xanthoma eruptum (also called eruptive xanthoma) is a skin condition characterized by the sudden appearance of numerous, small, yellow‑orange papules that often cluster on the trunk, buttocks, and extensor surfaces of the limbs. The lesions result from the deposition of lipid‑rich macrophages (foam cells) in the dermis.

Although eruptive xanthomas can occur at any age, they are most commonly seen in children and young adults who have severe, untreated hyperlipidemia—particularly marked elevations of triglycerides.

Typical age of onset	Infancy to early 30s
Gender distribution	Both sexes equally; slight male predominance in some series
Prevalence	Rare; exact incidence unknown. In large lipid clinic cohorts, eruptive xanthomas are reported in <1%–5% of patients with severe hypertriglyceridemia.

The condition is usually a cutaneous marker of an underlying metabolic disorder, most frequently familial hypertriglyceridemia, type V hyperlipoproteinemia, diabetic ketoacidosis, or secondary causes such as excessive alcohol intake, certain medications, or uncontrolled diabetes.

Symptoms

The hallmark of eruptive xanthoma is the appearance of multiple skin papules. Additional symptoms may accompany the primary lesions, especially when the underlying metabolic disease is active.

• Skin lesions
  • Small (2–5 mm), firm, dome‑shaped papules.
  • Yellow‑orange to flesh‑colored; may have a reddish halo.
  • Commonly distributed on the buttocks, thighs, shoulders, back, and extensor surfaces of the arms.
  • Lesions may coalesce into larger plaques if left untreated.
• Itching or mild tenderness – some patients report pruritus, especially when lesions become inflamed.
• Systemic signs related to hyperlipidemia
  • Pancreatitis (abdominal pain, nausea, vomiting) in severe hypertriglyceridemia.
  • Fatigue, blurred vision, or polydipsia in uncontrolled diabetes.
• Family history clues – relatives with early‑onset cardiovascular disease or known lipid disorders.

Causes and Risk Factors

Eruptive xanthomas are not a primary disease; they are a manifestation of excessive circulating lipids that overflow into the skin. The most common pathways include:

Primary (genetic) causes

• Familial hypertriglyceridemia (FHTG) – autosomal dominant disorder with triglycerides 200–500 mg/dL (2.3–5.7 mmol/L).
• Type V hyperlipoproteinemia – elevated chylomicrons and VLDL; often presents in childhood.
• Familial combined hyperlipidemia – variable patterns of high triglycerides, LDL‑C, or both.
• Genetic lipid storage diseases (e.g., sitosterolemia).

Secondary causes

• Uncontrolled type 1 or type 2 diabetes mellitus (especially with ketoacidosis).
• Excessive alcohol consumption – raises VLDL production.
• Medications: retinoids, beta‑blockers, thiazide diuretics, estrogen therapy, protease inhibitors.
• Obesity and metabolic syndrome.
• Hypothyroidism.

Risk factors

• Family history of hyperlipidemia or early cardiovascular disease.
• Age <35 years when triglycerides exceed 1,000 mg/dL (11.3 mmol/L).
• Pregnancy (physiologic rise in triglycerides) combined with a genetic predisposition.
• Diet high in simple sugars, saturated fats, and alcohol.

Diagnosis

Diagnosing eruptive xanthoma involves a combination of clinical assessment, laboratory testing, and occasionally skin biopsy.

1. Clinical examination

• Recognition of characteristic papules and their distribution.
• Assessment for other cutaneous xanthomas (tuberous, tendinous, planar) that may suggest chronic lipid disorders.

2. Laboratory investigations

• Lipid panel – fasting triglycerides, total cholesterol, LDL‑C, HDL‑C. Levels > 1,000 mg/dL (11.3 mmol/L) are strongly associated with eruptive lesions.
• Blood glucose & HbA1c – to identify uncontrolled diabetes.
• Liver function tests – rule out hepatic causes of dyslipidemia.
• Thyroid function tests – TSH, free T4.
• In selected cases, genetic testing for known lipid‑metabolism mutations.

3. Skin biopsy (rarely needed)

When the diagnosis is uncertain, a 4‑mm punch biopsy shows collections of lipid‑laden macrophages (foam cells) within the superficial dermis, confirming a xanthoma.

4. Imaging (if complications suspected)

• Abdominal ultrasound or CT if pancreatitis is suspected.
• Coronary artery calcium scoring in patients with very high LDL‑C or long‑standing hyperlipidemia.

Treatment Options

Therapy is two‑pronged: (1) rapid reduction of serum triglycerides to clear skin lesions, and (2) long‑term management of the underlying lipid disorder to prevent recurrence.

1. Immediate lipid‑lowering measures

• Fasting and low‑fat diet – eliminate simple sugars, refined carbs, and saturated fats; emphasize omega‑3‑rich fish, nuts, and fiber.
• Intravenous insulin infusion (in cases of diabetic ketoacidosis) – drives triglycerides into peripheral tissues.
• Plasmapheresis – reserved for triglycerides > 2,000 mg/dL with acute pancreatitis or refractory cases.

2. Medications

• Fibrates (gemfibrozil, fenofibrate) – first‑line agents; can reduce triglycerides by 30‑50%.
• Omega‑3 fatty acid ethyl esters (eicosapentaenoic acid, docosahexaenoic acid) – 2‑4 g/day lowers TG 20‑30%.
• Niacin (nicotinic acid) – decreases VLDL production; limited use due to flushing and hepatotoxicity.
• Statins – primarily lower LDL‑C but have modest TG‑lowering effect; may be added if LDL is also high.
• GLP‑1 receptor agonists or SGLT2 inhibitors – in diabetic patients, improve glycemic control and modestly reduce TG.

3. Lifestyle modifications

• Weight reduction – 5‑10% body weight loss can drop triglycerides 15‑20%.
• Alcohol restriction – ≤ 1 standard drink/day for men, ≤ 0.5 for women.
• Regular aerobic exercise – 150 min/week of moderate intensity.
• Smoking cessation – reduces cardiovascular risk.

4. Monitoring and follow‑up

Re‑check fasting lipid panel within 4–6 weeks of starting therapy. Skin lesions usually fade within weeks of achieving triglycerides < 500 mg/dL (5.6 mmol/L).

Living with Xanthoma Eruptum

Even after lesions resolve, patients must adopt habits that keep lipid levels in range.

• Track your labs – keep a log of lipid results and medication doses.
• Nutrition planning – use a registered dietitian to design a personalized low‑TG diet.
• Medication adherence – set reminders; discuss side effects with your clinician before stopping any drug.
• Skin care – moisturize to prevent itching; avoid traumatic removal of lesions (which can cause scarring).
• Regular check‑ups – at least annually with a lipid specialist or endocrinologist.
• Family screening – encourage first‑degree relatives to have a lipid panel, especially if a genetic cause is suspected.

Prevention

Because eruptive xanthomas signal an underlying metabolic problem, primary prevention focuses on keeping triglycerides and overall lipids normal.

• Maintain a BMI < 25 kg/m².
• Adopt a Mediterranean‑style diet: abundant fish, olive oil, legumes, whole grains, and limited red meat.
• Limit added sugars to < 10% of daily calories (≈ 50 g for a 2,000‑calorie diet).
• Exercise most days of the week; incorporate both aerobic and resistance training.
• Control blood glucose early in diabetes; aim for HbA1c < 7% (or as individualized).
• Screen for hyperlipidemia at age 9‑11 (per American Academy of Pediatrics) and again at puberty; earlier if family history is positive.

Complications

If the underlying hyperlipidemia remains uncontrolled, several serious complications can arise:

• Acute pancreatitis – triglycerides > 1,000 mg/dL raise risk 5‑10‑fold; can be life‑threatening.
• Cardiovascular disease – elevated LDL‑C and triglycerides accelerate atherosclerosis, leading to myocardial infarction or stroke.
• Hepatic steatosis – fatty liver disease may progress to non‑alcoholic steatohepatitis (NASH) and cirrhosis.
• Secondary xanthomas – tendinous, tuberous, or planar lesions can develop on tendons, eyelids, or dorsal hands.
• Psychosocial impact – visible skin lesions may cause embarrassment, anxiety, or reduced quality of life.

When to Seek Emergency Care

---

References:

• Mayo Clinic. “Eruptive xanthoma.” Accessed May 2026. mayoclinic.org
• American Heart Association. “Hypertriglyceridemia.” 2024 guidelines.
• National Institutes of Health, National Lipid Association. “Management of Severe Hypertriglyceridemia.” 2023.
• Cleveland Clinic. “Fibrates for high triglycerides.” 2025.
• World Health Organization. “Global report on diabetes.” 2022.

```